SK282308B6 - Použitie terpénov na výrobu farmaceutického prostriedku - Google Patents

Použitie terpénov na výrobu farmaceutického prostriedku Download PDF

Info

Publication number: SK282308B6
Authority: SK; Slovakia
Prior art keywords: derivatives; terpenes; cineol; manufacture; pharmaceutical composition
Prior art date: 1993-06-13

Application number

SK303-95A

Other languages

English (en)

Slovak (sk)

Other versions

SK30395A3 (en

Inventor

Uwe R. Juergens

Original Assignee

Uwe R. Juergens

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-06-13

Filing date

1994-06-11

Publication date

2002-01-07

1993-06-13 Priority claimed from DE19934319556 external-priority patent/DE4319556C2/de

1993-06-13 Priority claimed from DE4319554A external-priority patent/DE4319554C2/de

1994-06-11 Application filed by Uwe R. Juergens filed Critical Uwe R. Juergens

1995-11-08 Publication of SK30395A3 publication Critical patent/SK30395A3/sk

2002-01-07 Publication of SK282308B6 publication Critical patent/SK282308B6/sk

Links

235000007586 terpenes Nutrition 0.000 title claims abstract description 43
-1 terpene compounds Chemical class 0.000 title claims abstract description 32
238000004519 manufacturing process Methods 0.000 title claims description 39
239000000825 pharmaceutical preparation Substances 0.000 title description 2
238000011282 treatment Methods 0.000 claims abstract description 26
239000003246 corticosteroid Substances 0.000 claims abstract description 14
229960001334 corticosteroids Drugs 0.000 claims abstract description 13
238000011321 prophylaxis Methods 0.000 claims abstract description 10
208000027866 inflammatory disease Diseases 0.000 claims abstract description 8
229960005233 cineole Drugs 0.000 claims description 50
229930007050 cineol Natural products 0.000 claims description 46
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 26
BWRHOYDPVJPXMF-UHFFFAOYSA-N carane Chemical compound C1C(C)CCC2C(C)(C)C12 BWRHOYDPVJPXMF-UHFFFAOYSA-N 0.000 claims description 25
BEWYHVAWEKZDPP-UHFFFAOYSA-N bornane Chemical compound C1CC2(C)CCC1C2(C)C BEWYHVAWEKZDPP-UHFFFAOYSA-N 0.000 claims description 24
CFJYNSNXFXLKNS-UHFFFAOYSA-N p-menthane Chemical compound CC(C)C1CCC(C)CC1 CFJYNSNXFXLKNS-UHFFFAOYSA-N 0.000 claims description 24
XOKSLPVRUOBDEW-UHFFFAOYSA-N pinane Chemical compound CC1CCC2C(C)(C)C1C2 XOKSLPVRUOBDEW-UHFFFAOYSA-N 0.000 claims description 24
230000002757 inflammatory effect Effects 0.000 claims description 20
208000006673 asthma Diseases 0.000 claims description 15
239000008194 pharmaceutical composition Substances 0.000 claims description 15
229940114079 arachidonic acid Drugs 0.000 claims description 13
235000021342 arachidonic acid Nutrition 0.000 claims description 13
208000010668 atopic eczema Diseases 0.000 claims description 13
150000003505 terpenes Chemical class 0.000 claims description 13
XETQTCAMTVHYPO-UHFFFAOYSA-N Isocamphan von ungewisser Konfiguration Natural products C1CC2C(C)(C)C(C)C1C2 XETQTCAMTVHYPO-UHFFFAOYSA-N 0.000 claims description 12
230000000172 allergic effect Effects 0.000 claims description 12
229930006742 bornane Natural products 0.000 claims description 12
229930006741 carane Natural products 0.000 claims description 12
229930004008 p-menthane Natural products 0.000 claims description 12
229930006728 pinane Natural products 0.000 claims description 12
230000015572 biosynthetic process Effects 0.000 claims description 11
210000005260 human cell Anatomy 0.000 claims description 11
208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 8
102000004127 Cytokines Human genes 0.000 claims description 7
108090000695 Cytokines Proteins 0.000 claims description 7
150000003904 phospholipids Chemical class 0.000 claims description 7
230000001154 acute effect Effects 0.000 claims description 5
230000001684 chronic effect Effects 0.000 claims description 5
208000027775 Bronchopulmonary disease Diseases 0.000 claims description 4
208000015181 infectious disease Diseases 0.000 claims description 4
239000003018 immunosuppressive agent Substances 0.000 claims description 3
206010003210 Arteriosclerosis Diseases 0.000 claims description 2
208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
206010003230 arteritis Diseases 0.000 claims description 2
210000001188 articular cartilage Anatomy 0.000 claims description 2
208000001297 phlebitis Diseases 0.000 claims description 2
206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
238000009097 single-agent therapy Methods 0.000 claims description 2
230000009885 systemic effect Effects 0.000 claims description 2
208000019553 vascular disease Diseases 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims 8
RBNWAMSGVWEHFP-UHFFFAOYSA-N trans-p-Menthane-1,8-diol Chemical compound CC(C)(O)C1CCC(C)(O)CC1 RBNWAMSGVWEHFP-UHFFFAOYSA-N 0.000 claims 6
229960003444 immunosuppressant agent Drugs 0.000 claims 2
206010027654 Allergic conditions Diseases 0.000 claims 1
208000023275 Autoimmune disease Diseases 0.000 claims 1
208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
229940079593 drug Drugs 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
230000004968 inflammatory condition Effects 0.000 claims 1
210000004072 lung Anatomy 0.000 claims 1
230000000699 topical effect Effects 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 16
150000003431 steroids Chemical class 0.000 abstract description 10
239000002775 capsule Substances 0.000 abstract description 8
230000002829 reductive effect Effects 0.000 abstract description 5
238000012153 long-term therapy Methods 0.000 abstract description 4
125000002950 monocyclic group Chemical group 0.000 abstract description 4
239000000243 solution Substances 0.000 abstract description 4
238000000034 method Methods 0.000 abstract description 3
150000001875 compounds Chemical class 0.000 abstract 1
210000004051 gastric juice Anatomy 0.000 abstract 1
239000003978 infusion fluid Substances 0.000 abstract 1
238000010255 intramuscular injection Methods 0.000 abstract 1
239000007927 intramuscular injection Substances 0.000 abstract 1
230000003637 steroidlike Effects 0.000 abstract 1
WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 50
RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 12
WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 10
PSMFFFUWSMZAPB-UHFFFAOYSA-N Eukalyptol Natural products C1CC2CCC1(C)COCC2(C)C PSMFFFUWSMZAPB-UHFFFAOYSA-N 0.000 description 10
210000001616 monocyte Anatomy 0.000 description 10
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 6
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
229940041616 menthol Drugs 0.000 description 6
238000011866 long-term treatment Methods 0.000 description 5
230000004199 lung function Effects 0.000 description 5
229960005205 prednisolone Drugs 0.000 description 5
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 5
230000001629 suppression Effects 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 4
HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 4
230000007423 decrease Effects 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
210000004969 inflammatory cell Anatomy 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
230000007774 longterm Effects 0.000 description 4
230000009467 reduction Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 3
108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
230000037361 pathway Effects 0.000 description 3
LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 2
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
244000166124 Eucalyptus globulus Species 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
102000003777 Interleukin-1 beta Human genes 0.000 description 2
108090000193 Interleukin-1 beta Proteins 0.000 description 2
XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
102000015439 Phospholipases Human genes 0.000 description 2
108010064785 Phospholipases Proteins 0.000 description 2
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000009471 action Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
229960004544 cortisone Drugs 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
229960003973 fluocortolone Drugs 0.000 description 2
GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
230000037353 metabolic pathway Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
229960004618 prednisone Drugs 0.000 description 2
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
125000002006 1,8-cineol group Chemical group 0.000 description 1
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
CONVAEXWACQJSA-UHFFFAOYSA-N 3-oxabicyclo[2.2.2]octane Chemical compound C1CC2CCC1OC2 CONVAEXWACQJSA-UHFFFAOYSA-N 0.000 description 1
CNJLMVZFWLNOEP-UHFFFAOYSA-N 4,7,7-trimethylbicyclo[4.1.0]heptan-5-one Chemical compound O=C1C(C)CCC2C(C)(C)C12 CNJLMVZFWLNOEP-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
206010001889 Alveolitis Diseases 0.000 description 1
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
241000723346 Cinnamomum camphora Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
244000303040 Glycyrrhiza glabra Species 0.000 description 1
235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010025327 Lymphopenia Diseases 0.000 description 1
NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
240000005125 Myrtus communis Species 0.000 description 1
235000013418 Myrtus communis Nutrition 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
206010037549 Purpura Diseases 0.000 description 1
241001672981 Purpura Species 0.000 description 1
206010037596 Pyelonephritis Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
210000001132 alveolar macrophage Anatomy 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
210000003445 biliary tract Anatomy 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
229960004436 budesonide Drugs 0.000 description 1
229930008380 camphor Natural products 0.000 description 1
229960000846 camphor Drugs 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
208000003167 cholangitis Diseases 0.000 description 1
201000001352 cholecystitis Diseases 0.000 description 1
201000009151 chronic rhinitis Diseases 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
201000003146 cystitis Diseases 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000003344 environmental pollutant Substances 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
239000010642 eucalyptus oil Substances 0.000 description 1
230000003090 exacerbative effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
229960000676 flunisolide Drugs 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
239000003906 humectant Substances 0.000 description 1
208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
235000011477 liquorice Nutrition 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
231100001023 lymphopenia Toxicity 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
235000012245 magnesium oxide Nutrition 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
229930007503 menthone Natural products 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
231100000989 no adverse effect Toxicity 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
206010035653 pneumoconiosis Diseases 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
235000002020 sage Nutrition 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
208000000143 urethritis Diseases 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Steroid Compounds (AREA)
Pyrane Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SK303-95A 1993-06-13 1994-06-11 Použitie terpénov na výrobu farmaceutického prostriedku SK282308B6 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19934319556 DE4319556C2 (de)	1993-06-13	1993-06-13	Verwendung von 1,8-Cineol zur entzündungshemmenden Behandlung von steroidpflichtigem Asthma bronchiale
DE4319554A DE4319554C2 (de)	1993-06-13	1993-06-13	Verwendung von Menthol zur peroralen entzündungshemmenden Behandlung von Asthma bronchiale
PCT/EP1994/001900 WO1994028895A2 (fr)	1993-06-13	1994-06-11	Utilisation de composes terpeniques pour reduire la liberation d'acide arachidonique et de mediateurs d'inflammation

Publications (2)

Publication Number	Publication Date
SK30395A3 SK30395A3 (en)	1995-11-08
SK282308B6 true SK282308B6 (sk)	2002-01-07

Family

ID=25926728

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK303-95A SK282308B6 (sk)	1993-06-13	1994-06-11	Použitie terpénov na výrobu farmaceutického prostriedku

Country Status (19)

Country	Link
US (1)	US5889049A (fr)
EP (1)	EP0654994B1 (fr)
JP (1)	JPH08500612A (fr)
AT (1)	ATE173622T1 (fr)
AU (1)	AU680663B2 (fr)
BG (1)	BG62474B1 (fr)
BR (1)	BR9405404A (fr)
CA (1)	CA2140660A1 (fr)
CZ (1)	CZ285025B6 (fr)
DE (1)	DE59407336D1 (fr)
DK (1)	DK0654994T3 (fr)
ES (1)	ES2126123T3 (fr)
HU (1)	HUT69684A (fr)
NO (1)	NO313814B1 (fr)
PL (1)	PL308539A1 (fr)
RO (1)	RO111989B1 (fr)
RU (1)	RU2161482C2 (fr)
SK (1)	SK282308B6 (fr)
WO (1)	WO1994028895A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2693654B1 (fr) *	1992-07-20	1994-08-26	Oreal	Médicament, notamment immunomodulateur, contenant des enveloppes ou fractions d'enveloppes de bactéries filamenteuses non photosynthétiques et non fructifiantes, et sa préparation.
SE9604751D0 (sv) *	1996-12-20	1996-12-20	Astra Ab	New therapy
GB2329583A (en) *	1997-09-25	1999-03-31	Marilyn Rydstrom	Use of tea-tree oil for prophylaxis against cystitis
WO1999053935A1 (fr)	1998-04-16	1999-10-28	Ida Development A/S	Nouvelles compositions synergiques contenant des composes aromatiques et des terpenoides presents chez alpinia galanga
US6420435B1 (en)	1999-11-01	2002-07-16	Joe S. Wilkins, Jr.	Method for treating gastrointestinal disorders
US6733794B1 (en) *	1999-12-17	2004-05-11	Edward L. Ingram	Topical composition for antiseptic and analgesic purposes
US7041706B2 (en) *	2002-04-19	2006-05-09	Wilkins Jr Joe S	Method for treating crohn's disease
RU2210357C1 (ru) *	2002-04-26	2003-08-20	Леонова Наталия Сергеевна	Ароматический лечебно-профилактический состав доктора леоновой н.с.
US20080221029A1 (en) *	2002-10-31	2008-09-11	Regents Of The University Of Colorado	Methods for treatment of thiol-containing compound deficient conditions
US20040087527A1 (en) *	2002-10-31	2004-05-06	Day Brian J.	Methods for treatment of thiol-containing compound deficient conditions
US7790762B2 (en) *	2002-10-31	2010-09-07	National Jewish Health	Compounds and methods for thiol-containing compound efflux and cancer treatment
EP2320878B1 (fr) *	2008-09-04	2015-02-25	Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH	Monoterpène pour le traitement de maladies des voies respiratoires, en particulier de maladies bronchopulmonaires
DE202010007074U1 (de)	2010-05-12	2011-08-12	Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh	Neue Darreichungsformen für Cineol
DE102010022174A1 (de)	2010-05-12	2011-11-17	Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh	Neue Darreichungsformen für Cineol
WO2012049278A1 (fr) *	2010-10-15	2012-04-19	Medimmune Limited	Thérapies conçues pour améliorer la fonction pulmonaire
WO2012109216A1 (fr) *	2011-02-11	2012-08-16	Zx Pharma, Llc	Formulations de l-menthol multiparticulaires et procédés associés
DE102012001731A1 (de)	2012-01-20	2013-07-25	Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh	Systemische Darreichungsformen mit kontrollierter Freisetzung und verbesserter Stabilität
JP2012131823A (ja) *	2012-03-12	2012-07-12	Lotte Co Ltd	線毛運動活性化剤及びそれを含む飲食品

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4103019A (en) *	1975-10-07	1978-07-25	Laboratorios Landerlan, S. A.	Triterpene derivatives
ES8602818A1 (es) *	1983-10-31	1985-12-01	Merck Frosst Canada Inc	Una composicion farmaceutica
JP2524709B2 (ja) *	1985-09-26	1996-08-14	塩野義製薬株式会社	鎮痛消炎作用増強剤
US5120538A (en) *	1990-02-05	1992-06-09	Pt Darya-Varia Laboratoria	Combinations of compounds isolated from curcuma spp as anti-inflammatory agents
US5616458A (en) *	1990-03-14	1997-04-01	Board Of Regents, University Of Tx System	Tripterygium wilfordii hook F extracts and components, and uses thereof
AU7570191A (en) *	1990-03-14	1991-10-10	Board Of Regents, The University Of Texas System	Tripterygium wilfordii hook f extracts and components thereof for immunosuppression
US5580562A (en) *	1990-03-14	1996-12-03	Board Of Regents The University Of Texas System	Preparations and uses thereof for immunosuppression
JPH0426619A (ja) *	1990-05-18	1992-01-29	Lotte Co Ltd	抗アレルギー剤および抗アレルギー剤を含有する食品添加物
AU1783092A (en) *	1991-04-08	1992-11-02	United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The	Inhibitors of protein kinase c function
US5322689A (en) *	1992-03-10	1994-06-21	The Procter & Gamble Company	Topical aromatic releasing compositions
DE4211745A1 (de) *	1992-04-03	1993-10-07	Boerner Gmbh	Verwendung von Propolis und/oder seinen Fraktionen
US5338758A (en) *	1992-04-03	1994-08-16	Schering Corporation	Bicyclic diterpene PAF antagonist compounds
US5527890A (en) *	1993-04-16	1996-06-18	Glycomed Incorporated	Derivatives of triterpenoid acids and uses thereof
US5464754A (en) *	1993-08-17	1995-11-07	The Regents Of The University Of California	Assay and substrate for arachidonoyl-specific phospholipase A2
US5665386A (en) *	1995-06-07	1997-09-09	Avmax, Inc.	Use of essential oils to increase bioavailability of oral pharmaceutical compounds

1993
- 1993-06-11 CA CA002140660A patent/CA2140660A1/fr not_active Abandoned
1994
- 1994-06-11 HU HU9500714A patent/HUT69684A/hu unknown
- 1994-06-11 AU AU70003/94A patent/AU680663B2/en not_active Ceased
- 1994-06-11 AT AT94918864T patent/ATE173622T1/de active
- 1994-06-11 RU RU95109447/14A patent/RU2161482C2/ru active
- 1994-06-11 SK SK303-95A patent/SK282308B6/sk not_active IP Right Cessation
- 1994-06-11 DK DK94918864T patent/DK0654994T3/da active
- 1994-06-11 EP EP94918864A patent/EP0654994B1/fr not_active Expired - Lifetime
- 1994-06-11 PL PL94308539A patent/PL308539A1/xx unknown
- 1994-06-11 US US08/373,294 patent/US5889049A/en not_active Expired - Fee Related
- 1994-06-11 CZ CZ95370A patent/CZ285025B6/cs not_active IP Right Cessation
- 1994-06-11 RO RO95-00226A patent/RO111989B1/ro unknown
- 1994-06-11 DE DE59407336T patent/DE59407336D1/de not_active Expired - Lifetime
- 1994-06-11 JP JP7501336A patent/JPH08500612A/ja active Pending
- 1994-06-11 ES ES94918864T patent/ES2126123T3/es not_active Expired - Lifetime
- 1994-06-11 BR BR9405404A patent/BR9405404A/pt not_active Application Discontinuation
- 1994-06-11 WO PCT/EP1994/001900 patent/WO1994028895A2/fr not_active Ceased
1995
- 1995-02-10 NO NO19950518A patent/NO313814B1/no not_active IP Right Cessation
- 1995-03-13 BG BG99499A patent/BG62474B1/bg unknown

Also Published As

Publication number	Publication date
BR9405404A (pt)	1999-05-25
CZ285025B6 (cs)	1999-05-12
JPH08500612A (ja)	1996-01-23
EP0654994A1 (fr)	1995-05-31
NO950518L (no)	1995-02-10
BG99499A (bg)	1995-12-29
ATE173622T1 (de)	1998-12-15
RU2161482C2 (ru)	2001-01-10
EP0654994B1 (fr)	1998-11-25
CA2140660A1 (fr)	1994-12-22
ES2126123T3 (es)	1999-03-16
US5889049A (en)	1999-03-30
CZ37095A3 (en)	1995-11-15
WO1994028895A3 (fr)	1995-04-06
NO950518D0 (no)	1995-02-10
DK0654994T3 (da)	1999-08-09
WO1994028895A2 (fr)	1994-12-22
BG62474B1 (bg)	1999-12-30
HU9500714D0 (en)	1995-04-28
RO111989B1 (ro)	1997-04-30
PL308539A1 (en)	1995-08-21
HUT69684A (en)	1995-09-28
AU680663B2 (en)	1997-08-07
SK30395A3 (en)	1995-11-08
DE59407336D1 (de)	1999-01-07
AU7000394A (en)	1995-01-03
NO313814B1 (no)	2002-12-09

Legal Events

Date	Code	Title	Description
2014-03-04	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20130611

Publication	Publication Date	Title
SK282308B6 (sk)	2002-01-07	Použitie terpénov na výrobu farmaceutického prostriedku
Juergens et al.	1998	Antiinflammatory effects of euclyptol (1.8-cineole) in bronchial asthma: inhibition of arachidonic acid metabolism in human blood monocytes ex vivo
Juergens et al.	1998	Inhibition of cytokine production and arachidonic acid metabolism by eucalyptol (1.8-cineole) in human blood monocytes in vitro
JPH05213744A (ja)	1993-08-24	炎症性疾患の処置のための薬剤調製物
JP2026069510A (ja)	2026-04-23	心臓病態の治療に使用するためのカンナビジオール組成物
US20200330485A1 (en)	2020-10-22	Method and composition for reversing and/or inhibiting atherosclerosis
US10124012B2 (en)	2018-11-13	Method for treatment of hyperglycemia and hyperlipidemia
US11077137B2 (en)	2021-08-03	Method for treating diastolic heart failure by inhibiting galectin-3
JP2018516275A (ja)	2018-06-21	ナフトキノン系化合物を含む、膵炎を治療又は予防する組成物
CN113768956B (zh)	2025-08-15	无细胞脂肪提取液对巨噬细胞极化调节与疾病治疗的作用
JP3790686B2 (ja)	2006-06-28	血糖降下剤
WO2022114459A1 (fr)	2022-06-02	Composition pharmaceutique destinée à prévenir ou à traiter une fibrose d'organe, comprenant du fumarate de monométhyle en tant que principe actif
KR20230058590A (ko)	2023-05-03	연어과 오일 조성물을 사용하는 호흡기 치료
EP3270928B1 (fr)	2022-10-12	Utilisation du ginsénoside m1 pour la prévention ou le traitement de la goutte
Shaheen et al.	1989	Effect of praziquantel on some aspects of carbohydrate metabolism in mice infected with Schistosoma mansoni
CN104220083A (zh)	2014-12-17	用于治疗动脉硬化性血管疾病的方法和组合物
JP2007517853A (ja)	2007-07-05	心臓保護のための強心剤と組み合わせたジクロロアセテート
WO2005084693A1 (fr)	2005-09-15	Extrait de la graine de hippophae rhamnoides
EP2346502A1 (fr)	2011-07-27	Dérivés d'hypoestoxydes pour le traitement du paludisme
CN120938984A (zh)	2025-11-14	萝卜硫素在制备治疗血管内皮受损药物中的应用
AU2026203029A1 (en)	2026-05-07	Cannabidiol compositions for use in treating heart conditions
CN119656178A (zh)	2025-03-21	积雪草酸在制备抗动脉粥样硬化药物中的应用
JPH11189537A (ja)	1999-07-13	プロスタグランジン類の医薬用途
US20170105953A1 (en)	2017-04-20	Method for suppressing diabetes and/or hepatic lipids using tormentic acid
Shindo et al.	1996	In VivoEffect of Prednisolone on Release of Leukotriene B4 from Neutrophils from Asthmatic Patients